Skip to content

Basil Extract (Ocimum Basilicum) in the Management of Recurrent Aphthous Stomatitis

Muco-bioadhesive Gel Containing Basil Extract (Ocimum Basilicum) in the Management of Recurrent Aphthous Stomatitis: A Randomized Clinical Study

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04710888
Acronym
RCT
Enrollment
30
Registered
2021-01-15
Start date
2021-01-01
Completion date
2021-12-01
Last updated
2021-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral Ulcer

Keywords

Aphthous Stomatitis, basil extract, endocan marker

Brief summary

A randomized double-blind placebo controlled trial will be carried out on 20 patients complaining from aphthus ulcer and 10 patient healthy control 10 patients treated with mucoadhesive gel containing 2% of basil extract 4 times per day (test group) for 20 min after every meal and before going to bed. The other 10 patients treated by mucoadhesive gel without drug which was used as placebo (composed from 6% w/w PVA (Mw = 31-50 kDa, 98-99% hydrolysed) and 2% w/w sodium tetraydroxy borate) 4 times per day 10 healthy patients will be selected to participate in the study to test the salivary level of endocan in the healthy individuals (negative control group)

Detailed description

A randomized double-blind placebo controlled trial will be carried out on 20 patients complaining from aphthus ulcer and 10 patient healthy control. Inclusion criteria will be: (i) age \> 18 years; (ii) a clear history of RAS(recurrent apthous stomatitis)occurring no less than four times a year; (iii) presentation with one or two ulcers measuring 10 mm in diameter for 48 hours and yet to receive treatment; (iv) ulcers that took \> 5 days to resolve without treatment. Individuals will excluded if they: (i) had underlying systemic disease(s) or a history of immunologic disorder(s); (ii) were taking immunomodulatory agents or systemic nonsteroidal anti-inflammatory drugs \< 1 month before study commencement; (iii) are smokers; (iv) are pregnant; (v) had a history of abusing drugs or alcohol; (vi) could not provide written informed consent. 10 patients treated with mucoadhesive gel containing 2% of basil extract 4 times per day (test group) for 20 min after every meal and before going to bed. The other 10 patients treated by mucoadhesive gel without drug which was used as placebo (composed from 6% w/w PVA (Mw = 31-50 kDa, 98-99% hydrolysed) and 2% w/w sodium tetraydroxy borate) 4 times per day 10 healthy patients will be selected to participate in the study to test the salivary level of endocan in the healthy individuals (negative control group)

Interventions

DRUGuse of basil extract gel in treatment of aphthus ulcer

This study aimed to evaluate the efficacy of basil extract (Ocimum basilicum) in the treatment of aphthous ulcers

OTHERmuco adhesive placebo gel

mucoadhesive gel without drug which was used as placebo (contains tragacanth gum, alcohol, sodium benzoate, and distilled water) 4 times per day

OTHERno treatment

(i) had underlying systemic disease(s) or a history of immunologic disorder(s); (ii) were taking immunomodulatory agents or systemic nonsteroidal anti-inflammatory drugs \< 1 month before study commencement; (iii) are smokers; (iv) are pregnant; (v) had a history of abusing drugs or alcohol; (vi) could not provide written informed consent.

Sponsors

Tanta University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
15 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* age \> 18 years; * a clear history of RAS (recurrent apthous stomatitis) occurring no less than four times a year; * presentation with one or two ulcers measuring 10 mm in diameter for 48 hours and yet to receive treatment; * ulcers that took \> 5 days to resolve without treatment.

Exclusion criteria

* had underlying systemic disease(s) or a history of immunologic disorder(s); * were taking immunomodulatory agents or systemic nonsteroidal anti-inflammatory drugs \< 1 month before study commencement; * are smokers; * are pregnant; * had a history of abusing drugs or alcohol; * could not provide written informed consent

Design outcomes

Primary

MeasureTime frameDescription
pain score VAS (Visual Analogue Scale)one weekThe patients will be asked to record the daily level of pain severity of the ulcers through VAS (Visual Analogue Scale). It consisted of a 10-cm horizontal line, and the end of the line is (0) indicating no pain and the other end is (10) denoting unbearable pain.
healing durationone weekpatient evaluated by how long the ulcer takes to heal from baseline
size of the ulcerone weekmeasuring the ulcer size at baseline,5 days, and one week
salivary endocan levelone weekenzyme-linked immunosorbent assays to measure the salivary concentrations of endocan marker at the first visit (i.e., before treatment) and the other was just after healing

Countries

Egypt

Contacts

Primary Contactmalak m shoukheba
smalakyousefmohamed@yahoo.com+201012663927
Backup Contactmalak m shoukheba
smalakyousefmohamed@yahoo.com+20403335631

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026